PUMA BIOTECHNOLOGY, INC.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $29.6M | $69.2M | $84.6M | $76.2M | $63.1M | $85.3M | $60.0M | $108.4M |
| Accounts Receivable | $53.7M | $32.0M | $47.8M | $40.4M | $32.5M | $25.5M | $28.9M | $20.8M |
| Inventory | $5.5M | $8.7M | $7.1M | $4.5M | $7.1M | $3.5M | $3.2M | $2.6M |
| Total Current Assets | $162.7M | $147.7M | $156.2M | $134.3M | $140.0M | $146.1M | $166.3M | $203.0M |
| Property, Plant & Equipment | $187.0K | $515.0K | $855.0K | $1.1M | $1.8M | $2.5M | $3.3M | $4.0M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | $41.4M | $51.1M | $60.9M | $70.6M | $66.1M | $74.1M | $40.5M | $44.4M |
| Total Assets | $216.3M | $213.3M | $230.5M | $222.1M | $226.6M | $244.2M | $234.9M | $259.1M |
| Liabilities | ||||||||
| Accounts Payable | $5.1M | $5.5M | $6.9M | $6.4M | $11.2M | $12.1M | $19.2M | $20.7M |
| Total Current Liabilities | $81.3M | $96.1M | $99.4M | $77.5M | $109.6M | $114.3M | $90.8M | $67.1M |
| Long-Term Debt | $0 | $21.7M | $65.7M | $98.3M | $97.1M | $84.0M | $95.0M | $151.9M |
| Total Liabilities | $86.0M | $121.2M | $177.1M | $200.5M | $229.0M | $250.2M | $217.4M | $224.8M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.28B | $-1.31B | $-1.35B | $-1.37B | $-1.37B | $-1.34B | $-1.28B | $-1.20B |
| Total Stockholders' Equity | $130.3M | $92.1M | $53.4M | $21.6M | $-2.4M | $-6.0M | $17.5M | $34.3M |